Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

This study is testing C402-CD19-CAR — a personalized cell therapy where a patient's own T cells are engineered to seek out and kill lymphoma cells carrying a protein called CD19 — for people with large B-cell lymphoma that has come back or stopped responding to prior treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with CD19-positive large B-cell lymphoma (such as DLBCL or grade 3b follicular lymphoma), confirmed by biopsy - Your lymphoma has relapsed (come back) or is refractory (no longer responding to treatment) - You are in reasonably good physical condition - You are willing and able to follow the study protocol **You may NOT be eligible if...** - Your lymphoma is CD19-negative - You have active central nervous system lymphoma - You have serious organ problems (heart, liver, or kidney) - You have active uncontrolled infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.